Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors

References

• Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22(4): 239–58. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11): 450–6.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116(3): 496–526. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Porcelli S, Fabbri C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genetics and antidepressants: Where we are. Clin Neuropsychiatry 2011; 8(2): 99–150.
   Google Scholar
• Lee IS, Kim D. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res 2011; 34(11): 1799–816. [CrossRef]
   Web of Science ®Google Scholar
• Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27(7): 763–6.
   PubMed Web of Science ®Google Scholar
• Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33(2): 262–70. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Xu ZH, Wang W, Zhao XJ, Huang SL, Zhu B, He N, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol 1999; 48(3): 416–23. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280(2): 927–33.
   PubMed Web of Science ®Google Scholar
• Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7(1): 1–10. [CrossRef]
   PubMedGoogle Scholar
• Grasmäder K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60(5): 329–36. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, et al. Antidepressants and drug-metabolizing enzymes—expert group report. Acta Psychiatr Scand 1996; 93(2): 71–9. [CrossRef]
   Web of Science ®Google Scholar
• Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19(2): 170–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50(2): 195–200. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009; 9:38. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Weizman S, Gonda X, Dome P, Faludi G. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung 2012; 14(2): 87–101.
   PubMedGoogle Scholar
• Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002; 47(2): 174–80.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67–74. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Yilmaz S. Medication side effects and medication adherence in psychiatric patients. Master of science thesis. University of Istanbul, Institute of Health Science, Istanbul, 2004. (Turkish)
   Google Scholar
• Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55(12): 1128–32. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Y, Faries DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res 2011; 3:63–72.
   PubMedGoogle Scholar
• Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2012; 26(3): 398–407. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008; 64(12): 1181–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83(2): 322–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66(2): 185–92. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006; 26(4): 367–72. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70(1): 42–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 2007; 27(5): 451–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Gabriel A, Violato C. Knowledge of and attitudes towards depression and adherence to treatment: the Antidepressant Adherence Scale (AAS). J Affect Disord 2010; 126(3): 388–94. [CrossRef]
   Web of Science ®Google Scholar
• Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 2005; 66(2): 96–106. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rubio-Valera M, Serrano-Blanco A, Magdalena-Belío J, Fernández A, García-Campayo J, Pujol MM, et al. Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a systematic review and meta-analysis. Ann Pharmacother 2011; 45(1): 39–48. [CrossRef]
   PubMed Web of Science ®Google Scholar